Reference

Metabolism of exogenous coenzyme Q10 in vivo and the bioavailability of coenzyme Q10 preparations in Japan

Metabolism of exogenous coenzyme Q10 in vivo and the bioavailability of coenzyme Q10 preparations in Japan. Kishi, Hiroe; Kanamori, Nobuhiro; Nishii, Satoshi; Hiraoka, Eiichi; Okamoto, Tadashi; Kishi, Takeo (Dep. Pharm., Osaka Univ. Hosp., Osaka, Japan). Biomed. Clin. Aspects Coenzyme Q, 4, 131-42 (English) 1984. CODEN: BCAQDA. ISSN: 0167-8450. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) In order to clarify the metab. of absorbed coenzyme Q10 (CoQ10) [303-98-0], the product labeled in the isoprene chain was administered orally to rats previously fed a CoQ-free diet for 2 wk. In plasma, the isotope content peaked 2 h after administration and in tissues, it reached a max. after 6-24 h. At the peak, most of the isotope was found in the liver. Also, endogenous CoQ9 [303-97-9] and CoQ10 levels increased by ~20-35%. The isotope in the tissues, identified mostly as CoQ10, was released gradually once the plasma level had decreased. Thus, the plasma level of CoQ10 reflects the amt. absorbed and the tissue CoQ10 levels. When a dose of 60 mg equiv. CoQ10 formulation was administered to normal volunteers, the plasma CoQ10 level started increasing after 2 h and reached a max. after 6 h. It then decreased gradually and returned to the starting levels by 96 h after administration. The bioavailabilities of 6 of 166 CoQ10 com. prepns. were compared in crossover tests. The best prepn. (a soft capsule) increased the plasma level after 4 days to 2.7-fold the starting level, and the worst gave no increase at all. For the tablets and granules, the bioavailability of CoQ10 was correlated closely with the dissoln. rates and disintegration times.

The protection by coenzyme Q10 against experimental viral myocarditis in mice

The protection by coenzyme Q10 against experimental viral myocarditis in mice. Kishimoto, Chiharu; Tamaki, Shunichi; Matsumori, Akira; Tomioka, Nobuyoshi; Kawai, Chuichi (Fac. Med., Kyoto Univ., Kyoto, Japan). Jpn. Circ. J., 48(12), 1358-61 (English) 1984. CODEN: JCIRA2. ISSN: 0047-1828. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The effects of coenzyme Q10 (CoQ10) [303-98-0] on DBA/2 mice inoculated (on day 0) with the M variant of encephalomyocarditis virus were studied. There was no significant change in the cumulative incidence of myocarditis in the control and CoQ10 (0.1 mg/g/day, i.p., on days -1 to 12) groups. The survival rate was significantly higher on days 5-12 in the CoQ group than in the control group. There were no significant increases of coenzyme Q9 [303-97-9] content on days 3-4 and CoQ10 content on days 3-4 and 7 in the heart in the CoQ group as compared with the control group. There was no significant change in the serum content of coenzyme Q9 in both groups. The marked increase of the serum CoQ10 content seen in the CoQ group was due to the exogenous administration of CoQ10. Thus, CoQ10 may have a protective effect against viral myocarditis in man, in whom CoQ10 is only an active form of CoQ.